Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara

Saved in:

Bibliographic Details
Main Authors:	Caroline Staib, Marianne Löwel, Volker Erfle, Gerd Sutter
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2003-04-01
Series:	BioTechniques
Online Access:	https://www.future-science.com/doi/10.2144/03344bm02
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans
by: Alina Tscherne, et al.
Published: (2024-11-01)

Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).
by: Rachael Chiam, et al.
Published: (2009-06-01)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
by: Naif Khalaf Alharbi, et al.
Published: (2015-01-01)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
by: Ansar A Pathan, et al.
Published: (2007-10-01)

Transient Selection During Vaccinia Virus Recombination with Insertion Vectors Without Selectable Markers
by: Michael G. Kurilla
Published: (1997-05-01)

A Multi-Valent Hantavirus Vaccine Based on Recombinant Modified Vaccinia Ankara Reduces Viral Load in a Mouse Infection Model
by: Marilyn Aram, et al.
Published: (2025-03-01)

Design and construction of a fast synthetic modified vaccinia virus Ankara reverse genetics system for advancing vaccine development
by: Zhiqiang Gao, et al.
Published: (2025-04-01)

Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
by: Leonie Mayer, et al.
Published: (2024-11-01)

Construction of Recombinant Vaccinia Viruses Using PUV-Inactivated Virus as a Helper
by: Tatyana M. Timiryasova, et al.
Published: (2001-09-01)

Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
by: Leonie Mayer, et al.
Published: (2024-12-01)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
by: L. F. Stovba, et al.
Published: (2023-04-01)

Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer
by: Liying Sun, et al.
Published: (2025-01-01)

A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.
by: Javier Castillo-Olivares, et al.
Published: (2011-01-01)

Target Trial Emulation of the Modified Vaccinia Ankara-Bavarian Nordic Vaccine for Pre-Exposure Mpox Prevention in At-Risk Populations
by: Clara Suñer, et al.
Published: (2025-05-01)

Immunogenic and Protective Features of the Recombinant Vaccinia Virus Strain Expressing Cassette of Genes of Marburg Virus Structural Proteins
by: A. V. Semenova, et al.
Published: (2022-01-01)

Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker
by: Juana M. Sánchez-Puig, et al.
Published: (2005-11-01)

Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model
by: Cécile Herate, et al.
Published: (2025-08-01)

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.
by: Gavin Churchyard, et al.
Published: (2016-01-01)

Exploring the function and pathogenicity of Goatpox virus N1L gene using recombinant vaccinia virus Tiantan strain
by: Jialiang Xin, et al.
Published: (2025-07-01)

Recombinant chimeric horsepox virus (TNX-801) is attenuated relative to vaccinia virus strains in both in vitro and in vivo models
by: Stephanie V. Trefry, et al.
Published: (2024-12-01)

A loss of function analysis of host factors influencing Vaccinia virus replication by RNA interference.
by: Philippa M Beard, et al.
Published: (2014-01-01)

Vaccinia Virus Vector Bivalent Norovirus Vaccine
by: Yunbo Bai, et al.
Published: (2025-02-01)

Vaccinia Virus Immunomodulator A46: A Lipid and Protein-Binding Scaffold for Sequestering Host TIR-Domain Proteins.
by: Sofiya Fedosyuk, et al.
Published: (2016-12-01)

Research progress and development potential of oncolytic vaccinia virus
by: Xinyu Zhang, et al.
Published: (2025-04-01)

Isolation and Characterization of E8 Monoclonal Antibodies from Donors Vaccinated with Recombinant Vaccinia Vaccine with Efficient Neutralization of Authentic Monkeypox Virus
by: Yutao Shi, et al.
Published: (2025-04-01)

Temporal expression classes and functions of vaccinia virus and mpox (monkeypox) virus genes
by: Yining Deng, et al.
Published: (2025-04-01)

Immune Modulation in Primary Vaccinia virus Zoonotic Human Infections
by: Juliana Assis Silva Gomes, et al.
Published: (2012-01-01)

Advances of oncolytic vaccinia viruses armed with interleukin in tumor therapy
by: Mingyong Zha, et al.
Published: (2025-05-01)

Host range and specificity of the Drosophila C virus.
by: Martin Kapun, et al.
Published: (2010-08-01)

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
by: Richard N Greenberg, et al.
Published: (2016-01-01)

Strategies for the Modification of Vaccinia Virus towards a Better Vaccine Vector
by: Hao Sun, et al.
Published: (2025-01-01)

An Investigation on the Flora of Ankara-Ahlatlıbel Dryland Range and Distributions of Some Important Range Plant Species
by: Hayrettin Kendir, et al.
Published: (1997-08-01)

Narciclasine inhibits vaccinia virus infection by activating the RhoA signaling pathway
by: Ting Xu, et al.
Published: (2024-12-01)

Structure and function of A41, a vaccinia virus chemokine binding protein.
by: Mohammad W Bahar, et al.
Published: (2008-01-01)

Inhibition of IkappaB kinase by vaccinia virus virulence factor B14.
by: Ron A-J Chen, et al.
Published: (2008-02-01)

Differences in Mpox and Vaccinia Immunity Induced by Non-Replicating and Replicating Vaccinia-Based Vaccines
by: Getahun Abate, et al.
Published: (2025-05-01)

Exploring the recombinant evolution and hosts of crucivirus based on novel oyster-associated viruses
by: Hong-Sai Zhang, et al.
Published: (2025-02-01)

Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine.
by: Hong Chen, et al.
Published: (2012-01-01)

Inhibition of vaccinia virus L1 N-myristoylation by the host N-myristoyltransferase inhibitor IMP-1088 generates non-infectious virions defective in cell entry.
by: Lalita Priyamvada, et al.
Published: (2022-10-01)

Vaccinia virus induces rapid necrosis in keratinocytes by a STAT3-dependent mechanism.
by: Yong He, et al.
Published: (2014-01-01)